SELENOP and prostate carcinoma: These earlier studies have provided evidence that variants in a combination of the SEPP1 and manganese superoxide dismutase (SOD2) genes affects disease risk [18], that rs1050450 in GPX1 affects the influence of Se status on risk [13] and that variants in SEP15 affect prostate cancer survival [17].